AI Chat Paper
Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
● MetS is associated with significant hepatic fibrosis and steatosis in a cohort of patients with biopsy-proven NASH.
● NASH patients with MetS deserve more aggressive intervention and treatment.
● Greater awareness and risk stratification strategies are warranted to address the increasing burden of NASH.
Nonalcoholic steatohepatitis (NASH), an inflammatory form of non-alcoholic fatty liver disease, can progress to advanced liver fibrosis, cirrhosis, and liver cancer. Metabolic syndrome (MetS) parallels the prevalence of non-alcoholic fatty liver disease/NASH and increases patients’ risk of advanced liver disease. This study aimed to determine whether MetS was associated with the histological progression of NASH.
Patients with liver biopsy-proven NASH were retrospectively screened and categorized into two groups for each histological feature: with (<2 points) or without (≥2 points) significant hepatic steatosis/inflammation/fibrosis. Multivariable logistic regression was used to explore the association between MetS and histological features.
In total, 386 patients with a median age of 33.0 years were enrolled; among them, 35.2% were female, and 41.2% had MetS. The proportion of significant hepatic fibrosis and steatosis in those with MetS was significantly higher than in those without MetS (p < 0.05). Multivariable logistic regression analyses showed that MetS remained significantly associated with significant hepatic fibrosis (adjusted odds ratio: 1.852, 95% confidence interval: 1.042–3.292, p = 0.036), and severe hepatic steatosis (adjusted odds ratio: 2.008, 95% confidence interval: 1.030–3.914, p = 0.041).
MetS was associated with significant hepatic fibrosis and steatosis in patients with NASH. Our results suggest that NASH patients with MetS should be closely monitored and given targeted intervention and treatment, which may help to prevent disease progression and mitigate the growing burden of NASH.
Riazi K, Azhari H, Charette J, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61. https://doi.org/10.1016/S2468-1253(22)00165-0.
Powell EE, Wong VWS, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397(10290):2212–24. https://doi.org/10.1016/s140-6736(20)32511-3.
Zhang D, Wang H, He X, et al. MAFLD was more easily diagnosed than NAFLD in liver transplant recipients with abnormal liver function. iLIVER 2022;1(3):194–8. https://doi.org/10.1016/j.iliver.2022.09.001.
Singh SP, Anirvan P, Khandelwal R, et al. Nonalcoholic fatty liver disease (NAFLD) Name change: requiem or reveille? J Clin Transl Hepatol 2021;9(6):931–8. https://doi.org/10.14218/JCTH.2021.00174.
Lemieux I, Després JP. Metabolic syndrome: past, present and future. Nutrients 2020;12(11):3501. https://doi.org/10.3390/nu12113501.
Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2014;2(11):901–10. https://doi.org/10.1016/S2213-8587(14)70032-4.
Muzurović E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism 2021;119:154770. https://doi.org/10.1016/j.metabol.2021.154770.
Bence KK, Birnbaum MJ. Metabolic drivers of non-alcoholic fatty liver disease. Mol Metabol 2021;50:101143. https://doi.org/10.1016/j.molmet.2020.101143.
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–402. https://doi.org/10.1016/j.jhep.2015.11.004.
Te H, Doucette K. Viral hepatitis: guidelines by the American society of transplantation infectious disease community of practice. Clin Transplant 2019;33(9):e13514. https://doi.org/10.1111/ctr.13514.
Chalasani NP, Maddur H, Russo MW, et al. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2021;116(5):878–98. https://doi.org/10.14309/ajg.0000000000001259.
European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63(4):971–1004. https://doi.org/10.1016/j.jhep.2015.06.030.
Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012;32(1):3–13. https://doi.org/10.1055/s-0032-1306421.
Bedossa P, Pathology Consortium FLIP. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014;60(2):565–75. https://doi.org/10.1002/hep.27173.
Chinese Nutrition Society Obesity Prevention and Control Section, Chinese Nutrition Society Clinical Nutrition Section, Chinese Preventive Medicine Association Behavioral Health Section, et al. Expert consensus on obesity prevention and treatment in China. Zhonghua Liu Xing Bing Xue Za Zhi 2022;43(5):609–26. https://doi.org/10.3760/cma.j.cn112338-20220402-00253.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313–21. https://doi.org/10.1002/hep.20701.
Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13(3):372–4. https://doi.org/10.1016/0168-8278(91)90084-o.
European Association for Study of Liver, el Estudio del Higado ALP. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63(1):237–64. https://doi.org/10.1016/j.jhep.2015.04.006.
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4(5):389–98. https://doi.org/10.1016/S2468-1253(19)30039-1.
Radu F, Potcovaru CG, Salmen T, et al. The link between NAFLD and metabolic syndrome. Diagnostics 2023;13(4):614. https://doi.org/10.3390/diagnostics13040614.
Huang Y, Chen Z, Wang X, et al. Comparison of the three most commonly used metabolic syndrome definitions in the Chinese population: a prospective study. Metabolites 2022;13(1):12. https://doi.org/10.3390/metabo13010012.
Dewidar B, Kahl S, Pafili K, et al. Metabolic liver disease in diabetes—from mechanisms to clinical trials. Metabolism 2020;111S:154299. https://doi.org/10.1016/j.metabol.2020.154299.
Huang DQ, Wilson LA, Behling C, et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology 2023;165(2):463–72.e5. https://doi.org/10.1053/j.gastro.2023.04.025.
Kim KS, Hong S, Han K, et al. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ 2024:e076388. https://doi.org/10.1136/bmj-2023-076388.
Gong F, Zheng KI, Tang LJ, et al. Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor? iLIVER 2022;1(1):30–4. https://doi.org/10.1016/j.iliver.2022.02.001.
Alexopoulos AS, Crowley MJ, Wang Y, et al. Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease. Hepatology 2021;74(3):1220–33. https://doi.org/10.1002/hep.31806.
Eshraghian A, Fattahi MR, Taghavi A, et al. Metabolic syndrome, hepatic fibrosis, and steatosis diagnosed by liver stiffness measurement and controlled attenuation parameter after liver transplantation: the impact on long-term survival. Expet Rev Gastroenterol Hepatol 2022;16(10):1003–9. https://doi.org/10.1080/17474124.2022.2137488.
Alkhouri N, Almomani A, Le P, et al. The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. BMC Gastroenterol 2022;22(1):366. https://doi.org/10.1186/s12876-022-02430-7.
Cataldo I, Sarcognato S, Sacchi D, et al. Pathology of non-alcoholic fatty liver disease. Pathologica 2021;113(3):194–202. https://doi.org/10.32074/1591-951X-242.
Ahadi M, Molooghi K, Masoudifar N, et al. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36(6):1497–507. https://doi.org/10.1111/jgh.15353.
Sheka AC, Adeyi O, Thompson J, et al. Nonalcoholic steatohepatitis: a review. JAMA 2020;323(12):1175–83. https://doi.org/10.1001/jama.2020.2298.
Kamada Y, Takahashi H, Shimizu M, et al. Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol 2021;56(12):1045–61. https://doi.org/10.1007/s535-021-01833-9.
Amanullah I, Khan YH, Anwar I, et al. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. Postgrad Med 2019;95(1129):601–11. https://doi.org/10.1136/postgradmedj-2018-136364.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
